Drugs / ABT-957
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02573740 | Dec 2015 → Jun 2016 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT02220738 | Sep 2014 → Mar 2016 | Alzheimer disease | AbbVie | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-957 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02573740 ↗ |
| Action | Inhibit | “Alicapistat is an orally active selective inhibitor of calpain 1 and 2” PMID 30052328 ↗ Jul 2018 |
| Route | Oral | “Alicapistat is an orally active selective inhibitor of calpain 1 and 2” PMID 30052328 ↗ Jul 2018 |